Skip to Content
Merck
All Photos(1)

Key Documents

N1090000

Nizatidine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

N-{2-[2-(N,N-Dimethylaminomethyl)-4-thiazolylmethylthio]ethyl}-N′-methyl-2-nitro-1,1-ethenediamine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H21N5O2S2
CAS Number:
Molecular Weight:
331.46
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nizatidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+

InChI key

SGXXNSQHWDMGGP-IZZDOVSWSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nizatidine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Juan V Esplugues et al.
Medicina clinica, 127(20), 790-795 (2007-01-03)
The significant inhibitory capacity of gastric acid secretion of PPIs makes them the drugs of choice for treating acid-related diseases. The considerable prevalence of these diseases and the need for maintaining the administration of the drug during considerably long periods
Yin-Xia Chang et al.
The Analyst, 136(20), 4168-4173 (2011-08-23)
A validated, simple, and sensitive fluorescence quenching method for the determination of ranitidine, nizatidine, and cimetidine in tablets and biological fluids is presented. This is the first single fluorescence method reported for the analysis of all three H(2) antagonists. The
Sheila Seleri Marques Assunção et al.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 28(4), 270-276 (2007-01-24)
Weight gain is associated with treatment with many psychotropic agents. Nizatidine, H2 receptor antagonist, has been proposed to have weight-reducing effects. This was a 12-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of nizatidine in reducing/limiting weight gain in
Ibrahim A Darwish et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 69(1), 33-40 (2007-04-20)
A simple, accurate and sensitive spectrophotometric method has been developed and validated for determination of H(2)-receptor antagonists: cimetidine, famotidine, nizatidine and ranitidine hydrochloride. The method was based on the oxidation of these drugs with cerium(IV) in presence of perchloric acid
Sjogren's syndrome: promising, new treatment options besides nizatidine.
Shailendra Kapoor
Modern rheumatology, 19(1), 100-101 (2008-10-09)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service